{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:35Z","timestamp":1792177715672,"version":"4.4.0"},"reference-count":19,"publisher":"Portland Press Ltd.","issue":"16","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-15-RHUS-0004"],"award-info":[{"award-number":["ANR-15-RHUS-0004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Excessive activation of the mineralocorticoid receptor (MR) is implicated in cardiovascular and renal disease. Decreasing MR activation with MR antagonists (MRA) is effective to slow chronic kidney disease (CKD) progression and its cardiovascular comorbidities in animal models and patients. The present study evaluates the effects of the MR modulator balcinrenone and the MRA eplerenone on kidney damage in a metabolic CKD mouse model combining nephron reduction and a 60% high-fat diet. Balcinrenone and eplerenone prevented the progression of renal damages, extracellular matrix remodeling and inflammation to a similar extent. We identified a novel mechanism linking MR activation to the renal proteoglycan deposition and inflammation via the TLR4 pathway activation. Balcinrenone and eplerenone similarly blunted this pathway activation.<\/jats:p>","DOI":"10.1042\/cs20240302","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T09:25:45Z","timestamp":1722590745000},"page":"1025-1038","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR\/proteoglycan\/TLR4 pathway"],"prefix":"10.1042","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0867-1277","authenticated-orcid":false,"given":"Roberto","family":"Palacios-Ramirez","sequence":"first","affiliation":[{"name":"1Centre de Recherche des Cordeliers, Team Diabetes, Metabolic Diseases and Comorbidities, Sorbonne Universit\u00e9, Inserm, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Souli\u00e9","sequence":"additional","affiliation":[{"name":"1Centre de Recherche des Cordeliers, Team Diabetes, Metabolic Diseases and Comorbidities, Sorbonne Universit\u00e9, Inserm, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"Fernandez-Celis","sequence":"additional","affiliation":[{"name":"2Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"1Centre de Recherche des Cordeliers, Team Diabetes, Metabolic Diseases and Comorbidities, Sorbonne Universit\u00e9, Inserm, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabiha","family":"Boujardine","sequence":"additional","affiliation":[{"name":"1Centre de Recherche des Cordeliers, Team Diabetes, Metabolic Diseases and Comorbidities, Sorbonne Universit\u00e9, Inserm, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bonnard","sequence":"additional","affiliation":[{"name":"1Centre de Recherche des Cordeliers, Team Diabetes, Metabolic Diseases and Comorbidities, Sorbonne Universit\u00e9, Inserm, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Bamberg","sequence":"additional","affiliation":[{"name":"3Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3728-2606","authenticated-orcid":false,"given":"Natalia","family":"Lopez-Andres","sequence":"additional","affiliation":[{"name":"2Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9051-1901","authenticated-orcid":false,"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[{"name":"1Centre de Recherche des Cordeliers, Team Diabetes, Metabolic Diseases and Comorbidities, Sorbonne Universit\u00e9, Inserm, Universit\u00e9 de Paris, Paris, France"},{"name":"4Universit\u00e9 de Lorraine, INSERM Centre d'Investigations Cliniques-Plurith\u00e9matique 1433, UMR 1116, CHRU de Nancy, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"2024082213261328400_B1","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int."},{"key":"2024082213261328400_B2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"2024082213261328400_B3","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur. Heart J."},{"key":"2024082213261328400_B4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases","volume":"84","author":"Barrera-Chimal","year":"2022","journal-title":"Annu. Rev. Physiol."},{"key":"2024082213261328400_B5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1369\/0022155419849388","article-title":"Extracellular matrix in kidney fibrosis: more than just a scaffold","volume":"67","author":"B\u00fclow","year":"2019","journal-title":"J. Histochem. Cytochem."},{"key":"2024082213261328400_B6","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.3390\/ijms23126680","article-title":"Biglycan is a novel mineralocorticoid receptor target involved in aldosterone\/salt-induced glomerular injury","volume":"23","author":"Nakamura","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"2024082213261328400_B7","doi-asserted-by":"publisher","first-page":"859812","DOI":"10.3389\/fphys.2022.859812","article-title":"Mineralocorticoid receptor antagonism prevents the synergistic effect of metabolic challenge and chronic kidney disease on renal fibrosis and inflammation in mice","volume":"13","author":"Palacios-Ramirez","year":"2022","journal-title":"Front Physiol."},{"key":"2024082213261328400_B8","doi-asserted-by":"publisher","first-page":"0193380","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PloS ONE"},{"key":"2024082213261328400_B9","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1038\/s41598-021-82279-0","article-title":"Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models","volume":"11","author":"Bonnard","year":"2021","journal-title":"Sci. Rep."},{"key":"2024082213261328400_B10","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"2024082213261328400_B11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41371-020-0377-6","article-title":"Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease","volume":"35","author":"Wan","year":"2021","journal-title":"J. Hum. Hypertens."},{"key":"2024082213261328400_B12","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"2024082213261328400_B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.kisu.2021.11.004","article-title":"Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease","volume":"12","author":"Nakamura","year":"2022","journal-title":"Kidney Int. Suppl. (2011)"},{"key":"2024082213261328400_B14","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/bph.15734","article-title":"The mineralocorticoid receptor in chronic kidney disease","volume":"179","author":"Barrera-Chimal","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"2024082213261328400_B15","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12558","article-title":"TLR4 mutant mice are protected from renal fibrosis and chronic kidney disease progression","volume":"3","author":"Souza","year":"2015","journal-title":"Physiol. Rep."},{"key":"2024082213261328400_B16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41581-022-00590-z","article-title":"The fibrogenic niche in kidney fibrosis: components and mechanisms","volume":"18","author":"Li","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"2024082213261328400_B17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.matbio.2013.12.003","article-title":"De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88\/TRIF pathways","volume":"35","author":"Zeng-Brouwers","year":"2014","journal-title":"Matrix Biol."},{"key":"2024082213261328400_B18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1369\/0022155417738752","article-title":"Small Leucine-Rich Proteoglycans in Renal Inflammation: Two Sides of the Coin","volume":"66","author":"Nastase","year":"2018","journal-title":"J. Histochem. Cytochem."},{"key":"2024082213261328400_B19","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1161\/CIRCRESAHA.119.316427","article-title":"A new role for the aldosterone\/mineralocorticoid receptor pathway in the development of mitral valve prolapse","volume":"127","author":"Ibarrola","year":"2020","journal-title":"Circ. Res."}],"updated-by":[{"DOI":"10.1042\/cs-2024-0302_cor","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000}}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/doi\/10.1042\/CS20240302\/960282\/cs-2024-0302.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/doi\/10.1042\/CS20240302\/960282\/cs-2024-0302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T13:36:27Z","timestamp":1724333787000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/138\/16\/1025\/234770\/Mineralocorticoid-receptor-MR-antagonist"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":19,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,21]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20240302","relation":{"correction":[{"id-type":"doi","id":"10.1042\/CS-2024-0302_COR","asserted-by":"object"}]},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,8]]}}}